A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097. Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment. Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80  mg/m2 IV and RO4929097 10 mg daily given orally (PO) on days 1–3, 8–10 and 15–17 for six 21-day cycles. RO4929097 was escalated in 10 mg increments using the 3 + 3 dose escalation design. Two DLTs were observed in 14 patients - Grade (G) 4 thrombocytopenia in dose level 1 (10 mg) and G3 hypertension in dose level 2 (20 mg). Protocol-defined MTD was not determined due to discontinuation of RO4929097 development. However, 4 of 5 patients enrolled to 20 mg dose of RO4929097 required dose reduction to 10 mg due to toxicities (including neutropenia, thrombocytopenia and hypertens ion) occurring during and beyond the DLT observation period. Thus, 10 mg would have been the likely dose level for further development. G3 or higher hematologic toxicities included neutropenia (N = 8, 57%) and thrombocytopenia (N =&...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Source Type: research
Publication date: Available online 25 February 2020Source: Actas Urológicas Españolas (English Edition)Author(s): G. del Pozo Jiménez, F. Herranz Amo, J.A. Arranz Arija, E. Rodríguez Fernández, D. Subirá Ríos, E. Lledó García, G. Bueno Chomón, M.J. Cancho Gil, J. Carballido Rodríguez, C. Hernández Fernández
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Hi guys, I'm trying to gauge where I stand and am very confused due to my weird background. I took the MCAT in Jan and received a 524, but my GPAs are on the lower end. I am AA URM. GPA: 3.66c, 3.73s, 1 year 4.0 at end || 3.5 masters, 3.5 PhD first year (left see below) MCAT: 524 || Balanced, first take State: CA Race: URM, AA Clinical Volunteering: 250 hours - general hospital volunteer pulm unit 200 hours - driver for american cancer society patients 280... 3.66 cGPA, 3.73sGPA, 524 MCAT URM
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: What Are My Chances? WAMC Medical Source Type: forums
Publication date: Available online 25 February 2020Source: The Lancet Respiratory MedicineAuthor(s): Tony Kirby
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Authors: El-Demiry NM, Maged AM, Gaafar HM, ElAnwary S, Shaltout A, Ibrahim S, El-Didy HM, Elsherbini MM Abstract Objective: To evaluate the diagnostic performance of Doppler sonography of umbilical artery (UA), fetal middle cerebral artery (MCA), ductus venosus (DV) &umbilical vein (UV) for prediction of adverse perinatal outcome.Material and Methods: A prospective cohort study conducted on 60 women diagnosed  with preeclampsia with severe features divided into two groups based on adverse perinatal outcome.Results: Statistically Significant differences were demonstrated UA PI (1.28 ± 0.23 vs. 0.96 ± 0.21, P
Source: Hypertension in Pregnancy - Category: OBGYN Tags: Hypertens Pregnancy Source Type: research
Publication date: 2020Source: European Journal of Radiology Open, Volume 7Author(s): Anuradha Chandramohan, Umar M. Siddiqi, Rohin Mittal, Anu Eapen, Mark R. Jesudason, Thomas S. Ram, Ashish Singh, Dipti Masih
Source: European Journal of Radiology Open - Category: Radiology Source Type: research
Publication date: 1 June 2020Source: Personality and Individual Differences, Volume 159Author(s): Donald H. Saklofske
Source: Personality and Individual Differences - Category: Psychiatry & Psychology Source Type: research
Conclusion: These updated French guidelines will contribute to increase the level of urological care for the diagnosis and treatment for NMIBC and MIBC. PMID: 32093463 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Publication date: Available online 25 February 2020Source: The Lancet HIVAuthor(s): Fengyi Jin, I Mary Poynten, Andrew E Grulich
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research
Publication date: Available online 25 February 2020Source: The Lancet HIVAuthor(s): Helen Kelly, Admire Chikandiwa, Laia Alemany Vilches, Joel M Palefsky, Silvia de Sanjose, Philippe Mayaud
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Hematology | Hypertension | Investigational New Drugs | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Oral Cancer | Study | Thrombocytopenia | Toxicology